Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with
Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Assessment of the therapeutic efficacy of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Tumor and Organ Dose Estimates fromJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Safety of PSMA-Targeted Molecular Radioligand Therapy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Influence of increased injected activities up 9.0 GBq [EJNMMI physics · 2026Article
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2026Article
- The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer.Cancers · 2024Review
- PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.Frontiers in immunology · 2023Review
- From Concept to Regulatory Drug Approval: Lessons for Theranostics.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- [Pharmaceuticals (Basel, Switzerland) · 2022Review
- Advances in PSMA theranostics.Translational oncology · 2022Article
- Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.Molecular cancer therapeutics · 2022Article
- Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.Molecular diagnosis & therapy · 2022Review
Corrections and comments
- Commented on by
Authors and funding
23 authors at 5 institutions in 2 countries.
Jeremie Calais
Andrei GafitaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Matthias EiberAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Wesley R ArmstrongAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Jeannine GartmannAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Pan ThinAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Kathleen NguyenAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Vincent LokAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Laura GosaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Tristan GroganDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Rouzbeh EsfandiariExcel Diagnostics and Nuclear Oncology Center, Houston, Texas.
Martin Allen-AuerbachAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Andrew QuonAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Shadfar BahriAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Pawan GuptaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Linda GardnerAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
David RanganathanRadioMedix, Inc., Houston, Texas; and.
Roger SlavikAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Magnus DahlbomAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Ken HerrmannAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Ebrahim DelpassandExcel Diagnostics and Nuclear Oncology Center, Houston, Texas.
Wolfgang P FendlerAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
University of California, Los Angeles · USExcel Diagnostics Imaging · USUniversity of Duisburg-Essen · DEMolecular Theranostics (United States) · USRadioMedix (United States) · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5MUCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MNCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA211015
Abstract
The objective of this study was to determine prospectively the efficacy profile of 2 activity regimens of
Indexed as
Heterocyclic Compounds, 1-RingLutetiumNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAntigens, SurfaceCohort StudiesDipeptidesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedMolecular Targeted TherapyProspective StudiesProstate-Specific AntigenAntigens, SurfaceDipeptidesFOLH1 protein, humanGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumPluvictoProstate-Specific AntigenRadioisotopes177Lumetastatic castration-resistant prostate cancermolecular radiotherapyprospective randomized phase 2 trialprostate-specific membrane antigenradionuclide therapyRESIST-PCtheranostics
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.